AI-Generated Filing Summaries

Chair Rick Haythornthwaite purchased 2,132 shares, representing the largest transaction among the reporting directors.

Eight independent non-executive directors purchased shares ranging from 198 to 576 shares each.

All share purchases were executed at a price of £5.7700 per share on the London Stock Exchange.

Chair Rick Haythornthwaite purchased 2,132 shares, representing the largest transaction among the reporting directors.

Eight independent non-executive directors purchased shares ranging from 198 to 576 shares each.

All share purchases were executed at a price of £5.7700 per share on the London Stock Exchange.

CWCAM assumed general special servicing responsibilities for BANK 2018-BNK15 effective April 2, 2026, replacing LNR Partners.

CWCAM’s role excludes servicing of Non-Serviced Mortgage Loans and NCB Mortgage Loans per the Pooling and Servicing Agreement.

As of December 31, 2025, CWCAM served as special servicer for 330 domestic CMBS pools with $194.7 billion unpaid balance and 9,300 loans.

Sold 59 shares of Series D Preferred Stock at $1,000 each for $59,000 aggregate, plus 6 commitment shares.

Issued warrant for 243,750,000 common shares at $0.000161 exercise price, expiring March 26, 2031.

Series D Preferred has $1,200 stated value and 8% annual dividend paid quarterly in cash or shares.

The annual meeting will be held virtually on May 7, 2026, with shareholders of record as of March 9, 2026, eligible to vote.

Shareholders will vote on electing nine directors, reappointing KPMG LLP as auditor, and an advisory resolution on executive compensation.

The company reported 435,532,978 common shares outstanding as of March 9, 2026, and 435,457,978 as of December 31, 2025.

Cameco's 2025 Modern Slavery Report covers the financial year ended December 31, 2025, as required by the Fighting Against Forced Labour and Child Labour in Supply Chains Act.

The company considers modern slavery risk low in its controlled operations due to locations in Canada, the U.S., and Australia with established labor laws.

In 2025, Cameco sourced inputs from approximately 2,061 suppliers globally with total annual spend of approximately $1.264 billion for Canadian operations.

Form 6-K filed with Exhibit 99.1 (d711806dex991.pdf) on 2026-04-02.

Document items listed as N/A.

Content primarily consists of uuencoded PDF data with no discernible textual facts.

Separate trading of Class A Ordinary Shares and Warrants commences April 6, 2026.

Each Unit consists of one Class A Ordinary Share and one-quarter of one Warrant.

Whole Warrants trade only; no fractional Warrants will be issued upon separation.

David Lindberg received 1,034,617 ordinary shares valued at approximately £11.01 million, granted to buy out forfeited awards from his previous employer.

Of the total award, 128,664 shares vested immediately, with 60,473 shares sold to cover tax and social security liabilities, resulting in 68,191 net shares.

The remaining 905,953 shares are deferred awards vesting in annual tranches from March 2027 through March 2032, subject to 12-month retention periods.

David Lindberg received 1,034,617 ordinary shares valued at approximately £11.01 million, granted to buy out forfeited awards from his previous employer.

Of the total award, 128,664 shares vested immediately, with 60,473 shares sold to cover tax and social security liabilities, resulting in 68,191 net shares.

The remaining 905,953 shares are deferred awards vesting in annual tranches from March 2027 through March 2032, subject to 12-month retention periods.

The Federal Home Loan Bank of Indianapolis will assume primary obligation for $15 million in bonds on April 7, 2026.

The bonds carry a fixed 4.000% coupon rate and mature on April 7, 2028.

The bonds are callable at the FHLBank's discretion on specified dates starting January 7, 2027.

The Company declared a distribution for March 2026, with net amounts of $0.16000 per share for Class I and $0.14602 per share for Class S.

The distribution is payable to stockholders of record as of the open of business on March 31, 2026.

Payment will be made on or about April 9, 2026.

FHLBank issued $2.0 billion in consolidated obligation bonds across two separate CUSIPs.

Both issuances are Non-Callable Variable Single Index Floater bonds with short-term maturities.

Obligations are joint and several among the eleven Federal Home Loan Banks but not guaranteed by the U.S. government.

Granted Awards for 2,119,724 ordinary shares of US$0.50 each at GBP 0 purchase price on 31 March 2026.

Vesting over three years: 33% on first and second anniversaries, 34% on third; up to five years for Material Risk Takers.

Awards subject to 12-month post-vesting retention; certain tied to project completion or buy-out mirroring prior awards.

Granted Awards for 2,119,724 ordinary shares of US$0.50 each at GBP 0 purchase price on 31 March 2026.

Vesting over three years: 33% on first and second anniversaries, 34% on third; up to five years for Material Risk Takers.

Awards subject to 12-month post-vesting retention; certain tied to project completion or buy-out mirroring prior awards.

Scrip reference price set at US$13.834482 per new ordinary share for the 2025 second interim dividend.

Dividend amount is 18.89 US cents per ordinary share, payable under the Evergreen Scrip Dividend Scheme.

Minimum shareholding requirement of 74 ordinary shares on record date (27 March 2026) to participate in scrip alternative.

Scrip reference price set at US$13.834482 per new ordinary share for the 2025 second interim dividend.

Dividend amount is 18.89 US cents per ordinary share, payable under the Evergreen Scrip Dividend Scheme.

Minimum shareholding requirement of 74 ordinary shares on record date (27 March 2026) to participate in scrip alternative.

Company updated corporate presentation for investor meetings.

Presentation filed as Exhibit 99.1 to this 8-K.

Bank committed to two consolidated obligation bonds totaling $25 million par amount.

First bond: $10M, 4.730% fixed rate, matures 4/3/2036, Bermudan call from 4/3/2028.

Second bond: $15M, 4.000% fixed rate, matures 10/6/2028, European call on 10/6/2026.

FHLBank committed to issue $5M fixed-rate bond (5.75% coupon) maturing 4/13/2046 with optional principal redemption.

FHLBank committed to issue three variable Single Index Floater notes totaling $1.9B maturing between 8/4/2026 and 10/1/2026, all non-callable.

Consolidated obligations are joint and several liabilities of the eleven Federal Home Loan Banks, backed solely by their financial resources.

Account targets 75-85% net assets in direct real estate or related investments, holding 20.1% via joint ventures as of Dec 31, 2025.

Loan-to-value ratio was 18.4% as of Dec 31, 2025, below 30% guideline with 25% target.

Liquid fixed income investments targeted at 15-25% of net assets to support liquidity.

Executive Directors Deepak Nath and John Rogers received deferred share bonus awards on April 1, 2026, with 83,494 and 48,071 shares respectively, vesting on March 15, 2029.

Performance share awards were granted to 12 PDMRs under the Global Share Plan 2020 on April 1, 2026, with vesting subject to performance conditions measured from January 2026 to December 2028.

Restricted share awards were granted to 12 PDMRs under the Restricted Share Plan 2024 on April 1, 2026, vesting in equal annual tranches over three years, with additional conditions for the CEO and CFO.

Executive Directors Deepak Nath and John Rogers received deferred share bonus awards on April 1, 2026, with 83,494 and 48,071 shares respectively, vesting on March 15, 2029.

Performance share awards were granted to 12 PDMRs under the Global Share Plan 2020 on April 1, 2026, with vesting subject to performance conditions measured from January 2026 to December 2028.

Restricted share awards were granted to 12 PDMRs under the Restricted Share Plan 2024 on April 1, 2026, vesting in equal annual tranches over three years, with additional conditions for the CEO and CFO.

Annual general meeting scheduled for May 6, 2026 at 3:00 pm Mountain Time, virtual-only via specified link.

Formal business includes receiving 2025 financials, fixing 8 directors, electing directors, appointing Deloitte LLP as auditors, and advisory vote on executive compensation.

152,599,504 common shares outstanding as of March 18, 2026, traded as VET on TSX and NYSE.

Phase 3 trial (N=90) missed primary endpoint: no statistically significant HAM-D17 reduction vs placebo at hour 60.

Post hoc analysis (n=54 with psychiatric history) showed statistically significant HAM-D17 reductions vs placebo from hour 12 through day 30.

LPCN 1154 well tolerated with no AEs >5%, no SAEs, no discontinuations, supporting outpatient use.

Blue Bird acquired the remaining 50% interest in Micro Bird, becoming the sole owner of the joint venture enterprise.

The aggregate purchase price was $201,787,193, paid roughly 30% in cash ($63.0 million) and 70% in stock ($138.8 million).

The stock consideration involves 2,702,180 shares, issued as exchangeable shares subject to a six-month lock-up with staggered release through 2029.

John Achille promoted to President and COO effective immediately on April 1, 2026.

Achille retains oversight of Installation Services and Specialty Distribution day-to-day operations.

New responsibilities include Supply Chain organization and all growth initiatives such as M&A.

Michael K. Kneller, Vice President, General Counsel and Secretary since 2005, resigns May 8, 2026 to join Scopelitis, Garvin, Light, Hanson & Feary, P.C.

Vallie S. Dugas, current Vice President and Assistant General Counsel, named Interim Vice President, General Counsel and Secretary effective May 8, 2026.

Departure announced April 2, 2026.

EMERALD-3 Phase III trial met its primary endpoint of progression-free survival (PFS) with statistical significance in embolisation-eligible unresectable hepatocellular carcinoma (HCC).

The combination of Imfinzi, Imjudo, lenvatinib, and TACE showed a trend toward improved overall survival (OS) versus TACE alone at interim analysis.

The STRIDE regimen plus TACE arm also showed strong trends toward improved PFS and OS, although not formally tested at this time.

EMERALD-3 Phase III trial met its primary endpoint of progression-free survival (PFS) with statistical significance in embolisation-eligible unresectable hepatocellular carcinoma (HCC).

The combination of Imfinzi, Imjudo, lenvatinib, and TACE showed a trend toward improved overall survival (OS) versus TACE alone at interim analysis.

The STRIDE regimen plus TACE arm also showed strong trends toward improved PFS and OS, although not formally tested at this time.